PracticeUpdate Oncology May 2019

PRESCRIBE KISQALI WITH CONFIDENCE FOR: Proven efficacy • Over 2 years median PFS 2 • 43.2% reduction in risk of progression or death 2 (vs. placebo + letrozole; HR=0.568, 95% CI: 0.457 to 0.704, p<0.0001) • Improvement in efficacy across all patient subgroups and independent of treatment-free interval 2,3 Rapid response • 3 out of 4 patients saw a reduction in tumour size at Week 8 *2 *Subgroup analysis of patients with measurable disease at baseline. • Clinically meaningful improvement in pain score was seen as early as Week 8 and maintained up to Cycle 15 4 Predictable safety profile • Adverse events typically appeared early and resolved with appropriate management 2

UTI, neutropenia, leukopenia, anaemia, lymphopenia, decreased appetite, headache, insomnia, dyspnoea, back pain, nausea, diarrhoea, vomiting, constipation, stomatitis, abdominal pain, alopecia, rash, pruritus, fatigue, peripheral oedema, asthenia, pyrexia, abnormal LFTs, leukocyte count decreased, neutrophil count decreased, haemoglobin decreased, lymphocyte count decreased, platelet count decreased, ALT increased, AST increased, creatinine increased, phosphorous decreased, potassiumdecreased. Common (1-10%): thrombocytopenia, febrile neutropenia, lacrimation increased, dry eye, hypocalcaemia, hypokalaemia, hypophosphataemia, syncope, epistaxis, dysgeusia, dyspepsia, hepatotoxicity, erythema, peripheral oedema, weight decreased, ECG QT prolonged, bilirubin increased. Dosage: Adults - Kisqali 600 mg taken orally, once daily for 21 consecutive days followed by 7 days off treatment, in repeating cycles of 28 days. Caution in severe renal impairment and/ or moderate or severe hepatic impairment. Kisqali may require dose interruption, reduction, or discontinuation. Safety and efficacy not established in paediatrics, adolescents. Refer to full Kisqali PI and aromatase inhibitor PI. (kis120218m) ABBREVIATIONS: CDK, cyclin dependent kinase; HR+, hormone receptor positive; HER-, human epidermal growth factor receptor negative. REFERENCES: 1. Kisqali Product Information. 2. Hortobagyi GN et al. Ann Oncol 2018;29:1541–7. 3. Janni W et al. Breast Cancer Res Treat 2018;169:469–79. 4. Verma S et al. Breast Cancer Res Treat 2018;170:535–45.

Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. ® Registered Trademark. Item No: AU-8602. Date of preparation April 2019. 3291RC_PU_DPS.